Greetings. Welcome to the T2 Biosystems, Inc Q1 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Tripp Taylor. You may begin. Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems' future financial and operating results and plans for developing and marketing new products. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these statements, including the risks and uncertainties described in T2 Biosystems' annual report on Form 10-K filed with the SEC on March 31, 2023, and other filings the company makes with the SEC from time to time. The company undertakes no obligation to publicly update or revise any forward-looking statements except as required by law. With that, I would like to turn the call over to Chairman and CEO, John Sperzel. John? Thank you for joining our Q1 2023 earnings and business update call. Today, I will start by addressing two press releases that we issued earlier this morning, then discuss our performance during the Q1, including the progress we have made across our three corporate priorities as outlined in our Q1 earnings press release. I will then turn the call over to John Sprague, our Chief Financial Officer, who will review our Q1 financial results and our outlook for 2023, before I provide closing remarks and we open the call for questions and answers. This morning, we issued a press release announcing an FDA 510(k) submission for the T2Biothreat Panel, a product that we developed in collaboration with the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, or BARDA. The FDA submission marks an important milestone in our commitment to protect Americans from the threat of deliberate or naturally occurring outbreaks of biothreat pathogens, follows the recently completed U.S. clinical evaluation that demonstrated very high sensitivity and specificity, including 350 contrived positive samples and over 470 negative blood samples from both healthy and febrile subjects. The T2Biothreat Panel is a fully automated direct from blood test designed to run on the FDA-cleared T2Dx Instrument and simultaneously detects six biothreat pathogens identified as threats by the U.S. Centers for Disease Control and Prevention, or CDC, including the organisms that cause anthrax, tularemia, glanders, plague, and typhus. If not treated promptly, infections with these biothreat pathogens can result in mortality rates of 40%-90%. The T2Biothreat Panel is able to detect these biothreat pathogens within four hours directly from blood and provide clinicians with the needed information to appropriately treat infected patients. We believe the T2Biothreat Panel demonstrates very high sensitivity and specificity for a direct from blood multi-target biothreat product, and is the only such product developed by a U.S.-owned company, which we think will have an important factor in the discussions with the U.S. government regarding procurement of the T2Biothreat Panel. This morning, we also issued a press release announcing the exploration of a range of strategic alternatives focused on maximizing value and the implementation of a restructuring program. After careful consideration, the company has engaged an advisory firm to explore all potential strategic alternatives to maximize value, including an acquisition, merger, reverse merger, other business combination, sale of assets, licensing, and other strategic transactions. No updates on the process are expected to be provided during the evaluation period, unless and until the board of directors has concluded that disclosure is appropriate or required. A strategic restructuring program is being implemented to preserve capital and better position the company to explore all strategic alternatives while continuing to support its customers, pursue new commercial opportunities, and advance pipeline development. The restructuring program is designed to reduce annual operating costs and includes, among other things, an incremental reduction of the company's workforce by nearly 30%, which was completed last week. I will discuss further strategic changes in the context of our three corporate priorities. Turning to our recent business progress, the T2 Biosystems team has recently achieved a number of key milestones that position the company for success and support our mission to fundamentally change the way medicine is practiced through transformative culture-independent diagnostics that improves the lives of patients around the world. These accomplishments support our three corporate priorities: accelerating our sales, enhancing our operations, and advancing our pipeline. Starting with our first priority, accelerating our sales. Our commercial strategy is focused on increasing the adoption of our products with emphasis on increasing sales of our FDA-cleared sepsis test panels and expanding the installed base of our FDA-cleared T2Dx instruments. As we stated during our March 2023 earnings call, our top commercial priority will be increasing the use of our sepsis test panels with existing hospital customers. To drive increasing sepsis test revenue, we made two important changes to our sales strategy. The first change consists of expanding our sales targets to include larger hospitals and those that have a higher likelihood of achieving our annualized sepsis test panel utilization target of $200,000. Larger hospitals have shown greater potential for increased use of our T2Bacteria and T2Candida panels, given their increased patient volume and the number of patients that require complex treatments. At the same time, we acknowledge that larger hospitals have larger sales cycles, but believe balancing our sales funnel with a number of large hospital targets to complement our current targets of smaller and critical access hospitals provides greater opportunity for long-term sustained growth. The second change consists of shifting our sales incentive compensation plan to weigh more heavily on sepsis test revenue as compared to instruments. Ultimately, this is intended to align with our strategy of more time spent with legacy accounts, as well as to accelerate the time from when an instrument contract is signed to when the hospital goes live with patient testing. Our commercial medical affairs and support teams are closely integrated to ensure we can provide customers with the training and education required to ramp their utilization and realize the clinical and economic benefits offered by our sepsis products. During the Q1, we achieved sepsis and related product revenue of $1.7 million compared to $2 million in the prior year period, driven by lower instrument revenue. We also ended the Q1 with a sepsis test panel backorder of $230,000. We generated sepsis test panel revenue of $1.2 million, representing an 11% increase compared to the prior year period, despite ending the quarter with a $230,000 backorder. Had we been able to clear the backorder as of March 31st, the sepsis test panel increase would have been 34% compared to the prior year period. Importantly, we increased sales of T2Bacteria Panel by 55% globally, including a 109% increase in the U.S. market compared to the prior year period. We entered into contracts for five T2Dx Instruments during the Q1, all of which were sold outside of the United States market. We believe these results are representative of the change in our commercial strategy to focus more on increasing sepsis test panel utilization in legacy accounts and on larger hospitals with longer sales cycles. A strong validation of our new commercial strategy is that our U.S. T2Bacteria Panel revenues more than doubled in the Q1 of 2023 compared to the prior year period. This was supported by the adoption of four new hospital accounts ordering the T2Bacteria Panel for the first time, bringing our Q4 2022 instrument closes online in a faster timeline. We're pleased with the adoption rates of the T2Bacteria Panel as more hospitals are realizing the value of the product, as evidenced by the increased demand in our legacy accounts. We also have approximately 40 T2Dx Instruments in U.S. hospital laboratories that were initially sold for COVID-19 testing and which we are targeting for conversion to our sepsis test panels. I'm pleased to inform you that another instrument was converted to our sepsis test panels during the Q1 of 2023, and we expect additional conversions from COVID-19 to sepsis in the coming months. Separately, we're excited that we recently entered into multi-year pricing agreements with two large U.S. health systems, covering a total of 69 U.S. hospitals. The key hospitals in each of these two health systems are multi-year users of T2 Biosystems sepsis test panels. In those hospitals, our sepsis panels are integrated into the sepsis management protocols, and they're experiencing improved clinical benefits and positive economic benefits. The new agreements provide these 69 U.S. hospitals with contracted pricing for the T2Bacteria Panel and the T2Candida Panel for an initial year-year period, as well as options to procure T2Dx instruments. We're certainly excited about the opportunity to expand the use of our sepsis products within these two large health systems. Increasing sepsis test utilization within existing hospitals and expanding broadly across health systems are core tenets of our growth strategy and represent top U.S. commercial priorities. Internationally, there continues to be a significant commercial opportunity for our T2Dx instruments and sepsis test panels. This is reflected by continued sales of instruments and sepsis test panels to our international distributor partners. We continue to see strong demand in Europe and the Middle East, and expect to continue to expand distribution across the Asia-Pacific region in the coming months. Our efforts to increase awareness of the benefits of our sepsis test panels extend beyond the activities of our commercial team, medical affairs team, key opinion leaders, and scientific advisory board. In April, we presented clinical data at the European Society of Clinical Microbiology and Infectious Diseases, or ECCMID. Three presentations were delivered by clinicians highlighting their real-world experience, including the speed, accuracy, and clinical benefit delivered by our T2Dx Instrument and sepsis test panels. Driving awareness of the benefits of the T2 technology, combined with our optimized commercial game plan, gives us confidence in our ability to accelerate sales in the coming quarters. Moving to our second priority, enhancing our operations. We recognize that efficient operations are critical to our long-term success. To drive greater efficiency, we have taken measures to reduce expenses across the company. T2 Biosystems is now operating as a leaner organization with 110 employees, compared to 204 employees in May of 2022. We expect the net result of our workforce reduction and cost control measures to significantly reduce our quarterly cash burn throughout 2023. Driving increased leverage is a constant focus for our organization. We can achieve significant gross margin expansion as our customers continue to increase sepsis test panel utilization. Test panels carry a higher contribution margin, and as we increase test unit volumes, our overhead will be allocated across greater volume, which can lead to improved product gross margins. To support the growing demand for our sepsis test panels, our operations and manufacturing teams are hard at work managing the supply chain and continually improving our manufacturing process to drive greater efficiency. Over the last several months, we've strengthened our operations team by hiring a new vice president of operations and subsequently hired new manufacturing and supply chain leadership. On our March 2023 call, we discussed a raw material issue that we identified during our routine internal quality inspection that was limiting our ability to manufacture sufficient volume of sepsis test panels to meet customer demand. Considering we identified this issue during our in-process inspection, product that was shipped to customers or distributors was not affected. We're pleased to report that we have cleared the $230,000 backorder for the T2 Candida Panel and T2Bacteria Panel referenced earlier since the end of the Q1, and we're returning to more normalized shipment patterns for these products. We're still working through the materials issue for the T2Resistance Panel, and we expect to have it resolved before the end of the Q2. Finally, in the Q1, we strengthened our balance sheet by raising $12 million in gross proceeds. In the coming quarters, consistent with the workforce reduction that we implemented last week, we will continue to be disciplined with our operating expenses to increase our operating leverage and extend our cash runway. Moving to our third priority, advancing our pipeline. T2 Biosystems' novel technology platform and scientific expertise position the company to expand our addressable markets in the future. Our new product pipeline is focused on two goals. One, developing new tests to expand the test menu on the T2Dx Instrument. Two, developing a next-generation instrument and comprehensive sepsis panel. We're currently developing five new products to expand the test menu on our FDA-cleared T2Dx Instrument, including the T2Biothreat Panel, the T2Resistance Panel, the T2Lyme Panel, Candida auris, and Acinetobacter baumannii. Each new test panel or test represents a differentiated solution to rapidly identify harmful pathogens and potentially allow clinicians to achieve faster targeted therapy. We believe expanding the testing menu will increase both instrument adoption and test utilization. As we discussed the T2Biothreat Panel earlier in the call, I'll focus my comments on the four remaining menu expansion programs. First, T2Resistance Panel is a direct from blood molecular diagnostic test designed to simultaneously detect 13 antibiotic resistance genes known to cause antibiotic-resistant infections in just three-five hours without the need to wait days for a positive blood culture. The T2Resistance Panel, which is marketed and sold in Europe under CE mark, detects resistance genes that may confer resistance to common antimicrobials such as carbapenems, methicillin, and vancomycin. We have advanced the U.S. clinical trial and completed nearly 90% of patient enrollment and plan to file our submission to the FDA upon completion of the study. As a reminder, the T2 Resistance Panel was granted Breakthrough Device Designation by the FDA, which provides for a prioritized review upon submission and has received funding under our contract with BARDA. The T2 Lyme Panel is a direct from blood molecular diagnostic test to detect Borrelia burgdorferi, the bacteria that is the major cause of Lyme disease in the U.S. The T2 Lyme Panel is intended to test individuals with signs and symptoms of Lyme disease and aid in the diagnosis of early Lyme disease. We believe it will provide a significant advantage over the currently recommended serological testing that requires the presence of antibodies, which can take the body four to six weeks to create post-infection. In 2022, our T2Lyme Panel was named a winner in the LymeX Innovation Accelerator or LymeX, a partnership between the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation, the largest public-private partnership for Lyme disease that plans to award up to a total of $9 million to future award winners. We previously also received a patent from the U.S. Patent and Trademark Office covering the T2Lyme Panel, and FDA granted Breakthrough Device Designation for the T2Lyme Panel in 2022, allowing for a prioritized review process upon submission to the FDA. We have completed the early assay development for the T2Lyme Panel and established a preliminary level of detection, or LOD, of 2 CFU/mL. We plan to initiate commercialization of the T2Lyme Panel as a Laboratory Developed Test and subsequently commence a U.S. clinical trial to support submission for FDA clearance. Third, we plan to add Candida auris to our T2Candida Panel, a direct-from-blood molecular diagnostic test that detects over 90% of Candida bloodstream infections. Candida auris is a multi-drug resistant pathogen recognized by the CDC as a serious global health threat with a mortality rate up to 60%. According to CDC, Candida auris is difficult to identify with standard laboratory methods, which can lead to inappropriate treatment, and some strains are resistant to all three available classes of antifungals. The CDC estimates the costs associated with U.S. fungal diseases in general are as high as $48 billion annually and has called on public health professionals to lower the burden of fungal disease by continuing to raise awareness of the life-saving benefits of early detection and proper treatment. We believe adding Candida auris to our existing T2Candida Panel will provide a significant time advantage compared to other blood culture-based methods and strengthen the value proposition of the test Panel, making it even more attractive to our hospital customers. We've recently completed feasibility and early development of a diagnostic test to detect the Candida auris pathogen. I'm pleased to report that we also recently applied for FDA Breakthrough Device Designation for this test. Finally, we plan to add Acinetobacter baumannii to the T2Bacteria Panel, a direct from blood molecular diagnostic test to expand the number of pathogens detected on the test panel. Acinetobacter baumannii can cause bloodstream infections, especially in critically ill patients, which can range from benign transient bacteremia to septic shock, and is reported to have a crude ICU mortality rate of 34%-43%. Acinetobacter infections rarely occur outside of healthcare settings in the United States and can disproportionately impact those with weakened immune systems, chronic lung disease or diabetes. Acinetobacter can be resistant to many antibiotics, including carbapenems, highlighting the importance of rapid detection and targeted antimicrobial treatment. Looking ahead at longer term projects, we're focused on developing next generation sepsis products, including a new instrument and a comprehensive sepsis test panel. The next generation instrument is designed to increase the number of detections from a single whole blood sample. The comprehensive sepsis test panel is a direct from blood test designed to detect greater than 95% of all bloodstream infections caused by bacterial and Candida species and antibiotic resistance genes identified as threats by the CDC in a single test with a time to result of approximately three hours. The next generation instrument and comprehensive sepsis test panel have been funded under our contract with BARDA. We have been operating in option 3 of the BARDA contract after successfully meeting all development milestones under the base phase, option 1, option 2-A, and option 2-B. We have filed a no-cost extension with BARDA under option 3 to allow additional time to complete the U.S. clinical trial for the T2Resistance Panel. Further funding from BARDA may resume following the completion of option 3 and BARDA's potential exercise of option 4 of the contract. Considering timing is still and funding are uncertain, we are not providing guidance on BARDA revenue at this time. With that, I'll now turn the call over to John Sprague to provide detailed update on our Q1 financial results and our financial outlook for 2023. John? Thank you, John. Total revenue for the Q1 of 2023 was $2.1 million, a 71% decrease compared to the prior year period, driven by a decline in COVID-19 test sales and reduced BARDA revenues. Product revenue was $1.7 million, a decrease of 57% compared to the prior year period, driven by a 98% decline in COVID-19 test sales, partially offset by increased sepsis test sales. Research and contribution revenues were $400,000, an 88% decrease compared to the prior year period, driven by decreased BARDA contract activities. Cost of product revenue for the Q1 of 2023 was $4 million, a 35% decrease compared to the prior year period, driven by decreased COVID-19 test sales. Research and development expenses were $4.5 million, a 33% decrease compared to the prior year period, driven by decreased BARDA contract activities. Selling, general and administrative expenses were $7.3 million, a 21% decrease compared to the prior year period, driven by decreased medical affairs spending. Net loss for the Q1 of 2023 was $18 million, $1.32 per share, compared to a net loss of $16.5 million, $4.86 per share in the prior year period. Cash and cash equivalents were $10.1 million at March 31st, 2023. In the Q1 of 2023, we raised $1 million from ATM sales and $11 million from a public offering. The 30% workforce reduction will decrease our burn. We remain in compliance with our loan covenants. We reiterate guidance and expect 2023 total sepsis and related product revenue of $11 million-$13 million. Thank you, and back to John Sperzel for closing remarks. Thank you, John. Before I conclude, I'd like to address our Nasdaq listing compliance. On November 22nd, 2022, we received a letter from Nasdaq indicating that for the last 30 consecutive business days, the market value of listed securities had been below the $35 million minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). We were provided an initial period of 180 calendar days or until May 22nd, 2023 to regain compliance. We expect to receive a letter from Nasdaq informing us that our shares have failed to comply with the MVLS required for continued listing on the Nasdaq Capital Market, and as a result, our shares are subject to delisting. We will file an appeal and hearing request with Nasdaq, which Nasdaq must grant, which will stay the delisting of our common stock from the Nasdaq Capital Market pending a Nasdaq Listing Qualifications Hearing Panel's decision. There can be no assurance that the panel will grant our request for continued listing. However, we intend to present a plan to regain compliance to the panel that includes a discussion of the events that we believe will enable us to regain compliance in this timeframe. As a reminder, sepsis presents one of the greatest challenges to healthcare systems worldwide, claiming approximately 11 million lives each year. In the United States, sepsis is the number one cause of hospitalization, costing our healthcare system approximately $62 billion annually. The number one cause of death in hospitals, claiming the lives of approximately 270,000 Americans annually, another 80,000 deaths in hospice each year. Finally, the number one cause of 30-day hospital readmissions, requiring nearly 20% of sepsis survivors to be readmitted within 30 days and nearly 40% to be readmitted within 90 days. We are making progress to enhance the current standard of care for patients at risk of sepsis with our advanced diagnostic technology. We continue to be uniquely positioned as the only company with FDA-cleared diagnostics to detect sepsis-causing pathogens directly from whole blood samples. Our sepsis and related product revenue continues to grow, including sepsis test panels and instruments. We expect full year growth of 2023 of 31%-55%. The demand for our products is strong and our sales funnel continues to grow domestically and internationally. In an effort to maximize value, we also have taken important steps to reduce our operating expenses, including the restructuring program that was implemented last week. We have engaged an advisory firm to explore all potential strategic alternatives. Finally, we're making excellent progress advancing our product pipeline, including several near-term programs focused on expanding test menu on the FDA-cleared T2Dx Instrument and that have the potential to add revenue as early as 2023. I'd like to turn the call back over to the operator to open the line for questions. Operator? Certainly. At this time, we will be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment while we poll for questions. Your first question for today is coming from Kyle Mikson at Canaccord. Yeah. Hey, guys. Thanks for taking the questions. It's good to talk to you. I wanted to just kind of level set, John, on the timelines and priorities kind of going forward. I guess I'm curious how long it's going to take to kind of grow into your kind of relatively refreshed commercial strategy while you complete these, I guess, internal efforts to advance the pipeline assets, recognizing you have the BARDA partnership as well. How much time at the end of the day do you want to like allocate towards these buckets, and how do you think about, you know, priorities as you kind of try to limit cash burn as well? Thanks. Thanks, Kyle. The way we've set the three corporate priorities, one obviously is focused on commercialization. That team is in place. It's led by Brett Giffin. We have already evolved the sales team and the targets to focus on the targets that we have been prioritizing, which are sort of mid to critical access hospitals and supplemented that or enhanced it with a handful of large target accounts. That's underway. The comp plan has already been revised, and, you know, that's under specific leadership. The internal operating initiatives around manufacturing and cost controls, those obviously are led primarily on the cost side by John Sprague, but on the operating side by our new Vice President of Operations, that's Steve Miller. The pipeline is led by Roger Smith. We have different leadership that's focused on driving these initiatives and on balance we can do that. We're doing it with a much leaner organization, so there are certainly some things that we have decided not to do or we've decided to slow down a bit to make sure that we can extend our cash runway appropriately. Okay. That was helpful, John. Maybe, just thinking about the 11% year-over-year growth in the core product revenue. It sounded, you know, that's not overly impressive at first glance, but obviously, you have this $230,000 backorder that I guess came through in the Q2, but that would have been in the first. If that was in the first, it sounds like top line growth could have been 34%. That's which is solid. I guess going forward, I mean, does that, you know, kind of, you know, 30-plus% type growth for the next several quarters, a good way to think about your guys' financial performance? I mean, I just kind of that was a kind of an odd one-off, that backorder situation. How, how should we think about that, you know, variable kind of coming up in the, in the future? Sure. Well, when we set the guidance, we guided to sepsis and related product revenue of $11 million-$13 million, and we expected revenue to be weighted 40% H1 and 60% H2. If you split those halves, we also believed that the H1 would be 40% Q1 and 60% Q2, and same with the H2, 40% Q3 and 60% Q4. At the midpoint of $12 million, we expected 16% in Q1, 24% in Q2 and Q3, and 36% in Q4. If you look at that 16% that we expected in Q1 of the $12 million midpoint, it would've been $1.92 million. We finished at $1.7 million. We had 230 on backorder, so we were exactly where we expected to be. I guess I have a couple of questions off the kind of the guidance, I guess, too. I mean, just first with like, kind of a simple one on the placements. The five placements here, definitely less than what we were modeling. I mean, that's... It's not all bad if the install base is increasing at a relatively muted rate because then you're seeing maybe utilization kind of increasing faster, possibly. I mean, can maybe just talk about what you're seeing with utilization trends as some of these customers, you know, mature with their current platform or, you know, as the transition to sepsis kind of takes place and customers get more comfortable using those panels. Sure. First thing I would say, the five instruments that went to the international markets, those are all sold. That's good news because in the United States, we typically place those instruments. They go on our balance sheet, so they have a certain cost associated with them. It's in line with our strategy to drive sepsis test utilization. If you look at our installed base and our sales team, a sales team has a certain amount of hours that they can be selling in customer accounts. We've shifted that strategically to make sure that they're focused on driving increased utilization versus hunting for new accounts. Obviously, hunting for new accounts takes more time versus cultivating and growing the business in our existing accounts. In addition, we have those 40 instruments that were initially sold for COVID testing that we have been working to convert to sepsis testing. It's been a slower process than we anticipated. Carving out some of that sales force time so they can focus on driving those conversions are really important. Quite frankly, it's a lot more efficient use of the sales time. We'll get a much better return converting those 40 instruments that are already there than we would putting 40 new instruments into the market at this point in time. Okay, that's helpful. It's actually not clear to me, this $230,000 backorder, was that mainly instruments or is that consumables? 'Cause that could be a few instruments possibly too, I guess, right? I'm just curious about that. It was all consumables, and it was predominantly T2Candida panels and a little bit T2Bacteria. Gotcha. Okay. So the expectations for placements for the rest of 2023, the five in 1Q, I mean, I appreciate the dynamics of, you know, the, of buying and order selling versus placing, things like that. You know, it is quite the difference, I guess, when you're doing OUS versus U.S. Anyway, the five is the lowest since the stick of the pandemic, I think like early 2021. Will the rest of the 2023 performance, like what's in the guidance right here from 2Q to 4Q, is that gonna be driven by instrument revenue or panel revenue in your, in your guys' view? How does that split between U.S. and then international look like? Then maybe if you could just comment on the pipeline product revenue. It sounded like you could include some of that. You know, you're assuming maybe some this year. Is that in this guidance too? Because that's obviously could be upside. Thanks. I'll just take those in different order. Mm-hmm. There is not new product revenue in the guidance. For example, T2Lyme Panel or to the extent T2Biothreat Panel gets through FDA and is commercialized this year, that is not in our guide. That's the first thing I would say. As far as instruments are concerned, the five instruments in the quarter, it's obviously less than we anticipated. We didn't guide on instruments because of the emphasis and the focus on tests and test utilization. We anticipate instruments on a quarterly basis throughout the balance of the year being higher than five per quarter. Gotcha. Okay. If I could just ask a final one. I don't wanna take up too much time, but the, you know, maybe this 30% reduction, I think that... That's incremental to the, to the one that you did not too long ago, I think it was several quarters ago. Which departments were affected by this more recent reduction last week? All of them. Yeah. Okay. All right. Sounds good. All right. Thanks, John. Appreciate the time. Thank you, Kyle. Appreciate it. Your next question is coming from Mark Massaro at BTIG. Hey guys, thank you for taking the questions. Maybe just to follow up on that last one, if all the departments were impacted, maybe could you comment, John or Brett, on what the commercial organization looks like? I know you were down to maybe three reps or so. Just what does that look like, in terms of sales support, medical science liaisons, and others that can help drive the top line? Sure. Brett, would you like to take that one? Yeah, sure. Can you hear me okay? Yes. Okay, great. Hey, Mark, thanks for the question. Yeah, I mean, as John mentioned, there were some impacts in the recent moves that we made. I would say that across the board, if you look at it, I think they were, I'd say, more minimized on the commercial side of things if you just looked across the whole organization. Along with that, you know, Mark, as I had talked about in prior, you know, periods, you know, we've obviously endeavored to strengthen our medical affairs organization. We've done that. Same thing with marketing, with a change in leadership. Those two organizations were not affected in this latest. We did actually, you know, have a couple few positions here and there across sales and service. I, you know... Look, we feel very strongly about the team we have in place. Certainly we were, you know, very judicious about where those moves came from and, you know, are in the point now we feel very comfortable in being able to cover the account base with the right amount of focus. Yeah, I think we're... You know, I mean, these things are always, they have impacts. I sort of feel like on the commercial side of it and what we're doing that, you know, we largely minimize that. On the congrats on the multiyear pricing agreements with two large health systems. I'm curious if these are pricing agreements only, or were there any purchases or any orders that went with these? They are pricing agreements, Mark. Go ahead, Brett. No, I was just gonna say they're pricing agreements, Mark, with the, I think with the, I'll call it sort of the strong emphasis on tie-in with the sort of key anchor institutions, if you will, to help drive those in, you know, across the other institutions that are part of those networks. Yeah, they're principally pricing agreements. Correct. Okay. Is it fair to say that you would expect purchasing behavior or purchasing off of these pricing agreements as the year progresses or the quarter? Very much so. That these are for licenses to hunt, so to speak, I think much more not that we couldn't have in the past, but I think with a much stronger, I'd call it sort of tie in and connection with the mothership, so to speak. I think yes, I think we're very bullish about targeting those within those setups. Okay, great. I guess, you know, you guys have had a relatively low cash balance the last couple quarters. You know, I'm a little bit surprised, modestly surprised to see the news on the strategic alternative pursuit. Maybe can you guys comment? I think there's a statement in your 10-Q that you believe that you may not have enough cash, let me, may not have enough cash, I think, to get through June 30th or July, yet to fund its operating plans through June 30th. I'm trying to figure out, you know, has the cash burn spiked a little bit? Were there any one-timers? How much of the decision to pursue strategic alternatives is around the uncertainty on the no-cost extension from BARDA? I guess what I'm trying to figure out is, if BARDA does extend you, how do you expect that might impact, you know, your funding situation in the next, you know, several months? I'll let John take the cash question, but I would just address the one about pursuing potential strategic alternatives. It's completely unrelated to BARDA. Yeah. Just excuse me, just to add to the cash burn. Our cash burn has come down consistently, Mark, as we've leveraged operations, as well as it's gonna be benefited by the reduction in force. We do have some seasonality in terms of our procurement purchases, for pricing in our supply chain. You see that typically in Q1, and then it levels off during the rest of the year. You know, overall, going forward, we expect our burn to be significantly decreased as a result of all these efforts. Okay, great. I'll just add to that. Yeah. Mark, I'll just add to that. I mean, the going concern language in our 10-Q that we filed yesterday, that's not the first time that we've had going concern language, because as you noted, our cash balance has been relatively lean on a sort of quarterly basis over the last 12 months. Yeah. Okay. I guess, I think you've touched on this, but maybe I'll just make sure we're all on the same page. You know, saying you're not gonna have enough cash to get through June and then reiterating the full year sepsis guidance range of 11-13 after doing a nearly 30% reduction in force, I guess, what gives you confidence that you can still hit those numbers this year? Well, I think what that language says is that we're gonna need to raise capital. Yep, understood. Which is also clear. All right. Well, congrats on the growth in the T2Bacteria Panel, especially in the U.S. I guess maybe my last question, John, I guess can you explain what drove the triple-digit year-over-year revenue growth in T2Bacteria Panel? Were these predominantly the four new hospitals that came on? Or maybe can you just give us a sense for where that strength came from and what your, you know, near-term pipeline looks like to turn on T2Bacteria Panel? Sure. I'll start then Brett might wanna add to it. It certainly was a factor that we had four accounts come online. I'd say it's also a result of our renewed or modified sales strategy to focus on driving a broader adoption within these hospital accounts. The fact that, keep in mind, the T2Bacteria Panel launch happened shortly before the COVID pandemic. I don't think that hospital accounts have had the full benefit of our sales and marketing team and our scientific advisory board members championing the value of T2Bacteria and we're starting to see the impact of that. Brett, you wanna add anything to that? Yeah, I think that that's correct. Mark, you probably, you know, might recall too, we've been seeing a really solid lift in bacteria going, you know, going back into last year. I mean, you know, the H2 of last year, I think we've continued to accelerate that, you know, at obviously, you know, adding our medical affairs resources that we now have in place and having that integrated along, you know, as I mentioned with, you know, the marketing group and with sales all working together. I think it's, yeah, I mean, it's really borne a lot of fruit and it's, you know, it's a combination. We've certainly seen good solid lift within, you know, the legacy accounts both in the U.S. as well as internationally. Again, you know, as John mentioned, adding to that, you know, the new accounts that we've brought on are, you know, we're certainly seeing and experiencing the impact of that. Yeah, it's been a, been a great picture and I think it's certainly one we're bullish on going forward too. Excellent. Thanks for the time, guys. Thank you, Mark. Your next question is coming from Benjamin Haynor at Alliance Global Partners. Good morning, gentlemen. Thanks for taking the questions. First off for me, you know, congrats on completing the assay development for the T2Lyme. You know, what's left to do there before launch? You know, is this something that you're gonna launch yourself or look to a partner? Does the present balance sheet situation make you lean more towards a partner if there's some upfront money potentially available? Just any help there would be helpful. Thanks, Ben, for the question. We have to do a little bit of work on the instrument side to make sure that we marry that with the assay development work that's gone on. I think the really important point to underscore on the limit of detection that I described, that preliminary LOD of 2 CFU/mL, that's really critical because our focus from a marketing perspective is on early Lyme disease in that first 30 days, because the alternative tests that are in the market are relying on antibodies that take time to develop. This is in line with our strategy where rapid detection is important for targeted treatment. From a commercial perspective, you covered both areas, which is, are we gonna do this ourselves, are we gonna do it through a partner? We're exploring both opportunities and we haven't decided at this point. Okay. I presume there's some discussions going on, you know, certainly internally, but are you also discussing with potential partners and have, kind of engagements there? Yes, we are. Okay. Got it. We'll stay tuned there. Then on the 30% reduction in force, what's the right way to think about that in terms of expenses? I mean, is it, you know, kind of a 30% reduction in OpEx as well? Then, will there be any sort of charge in the current quarter, and what does that look like? There's no charge in the current quarter. John Sprague, would you take the kind of forward-looking OpEx, give Ben some insight on that? Yeah. I think it's fair to model somewhere between 20% and 30%, Ben. You know, it is skewed based on the mix of employees that were impacted. I think that that's a good way to view our burn improvement going forward. Okay. Got it. Lastly for me, and I'll take the rest offline, but, the T2Resistance trial, getting down to the short strokes here, Does that completing trigger any payment for BARDA, or does that require them picking up option four to have some more cash come in the door? I'd say first thing, we're super excited about both T2Biothreat and T2Resistance. Remember, we came into this year anticipating getting two products over the goal line submitted to the FDA that could potentially be revenue contributors this year. We have submitted T2Biothreat to the FDA, so that 90-day clock is now ticking. The FDA will respond to us sometime in mid-August, if not sooner, and we're excited about that. We're also excited about T2Resistance. We're close to the goal line on completing the clinical trial. We're 90% at this point, and we are under a no-cost extension. From a BARDA perspective, we don't anticipate additional funding for T2Resistance. Once we complete option 3, as I mentioned in the earlier prepared remarks, that would be a point where BARDA may potentially trigger payment under option 4, and then there is also a contemplated option 5 and option 6. Those, again assuming BARDA funds them, would be for the next gen instrument and comprehensive sepsis panel. Okay. Got it. appreciate the clarification there. That's it for me, gentlemen. Thanks for taking the questions. Thank you, Ben. Appreciate it. We have reached the end of the question and answer session, and I will now turn the call over to John Sperzel for closing remarks. Thank you very much for joining our Q1 2023 earnings call. Hope you all have a great day. This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation.